MedCity Invest

Event Date: Tue, 2017-05-16 18:00 to Thu, 2017-05-18 12:30


MedCity INVEST is the premier national healthcare investing conference based in the Midwest.

For well over a decade, this conference has united active investors with corporate business development executives to syndicate investment opportunities with promising start-ups from the biopharmaceutical, diagnostics, medical devices, digital health/health IT, and health services sectors.

Join us at the Four Seasons Chicago May 17-18, 2017 to hear from innovative investors, prominent industry players and 40+ startup companies—highlighting opportunities to invest in the most elite companies offering innovative approaches or trying to solve some of healthcare’s greatest challenges.

Make plans now to attend.

Reasons to Attend / Hear what past attendees say about MedCity INVEST.

Pre-Conference: Tuesday, May 16

6:00 PM

Opening Reception at MATTER Read more »

Day 1: Wednesday, May 17

8:00 AM–8:30 AM

Registration + Breakfast

8:30 AM–9:00 AM

Day 1 Opening Keynote

9:00 AM–10:00 AM

Panel: What’s Hot in Biopharma Investing?

In biopharma, is immune-oncology old news? What’s next after CRISPR? Hear from top investors about what’s new, novel and exciting in the industry sector that commands top dollar from VCs.

Kevin Bitterman, Partner, Polaris Partners



Kevin is a Partner in the Boston office of Polaris Partners. He joined Polaris in 2004 and focuses on investments in healthcare.  In his time at Polaris, Kevin co-founded Genocea Biosciences (NASDAQ: GNCA) and was the founding CEO of Editas Medicine (NASDAQ: EDIT), Morphic Therapeutic and Visterra. He currently represents Polaris as a director of Editas Medicine, InSeal Medical, Genocea Biosciences, Kala Pharmaceuticals, Morphic Therapeutic, Neuronetics, Taris Biomedical and Vets First Choice.

Kevin is active in the local life science and healthcare start-up community, serving on the Scientific Advisory Board of the Massachusetts Life Sciences Center (MLSC) and as Board Chair of the New England Venture Capital Association (NEVCA). Kevin received a BA, summa cum laude, from Rutgers University before completing his PhD in genetics at Harvard Medical School.

Outside of work Kevin enjoys spending time with his wife and two young daughters.  He also enjoys trail running and whiskey, though generally not at the same time.

Jack Gilbert, Co-Founder and Scientific Advisor, Gusto Global; Director, Microbiome Center, University of Chicago



Professor Jack A Gilbert earned his Ph.D. from Unilever and Nottingham University, UK in 2002, and received his postdoctoral training at Queens University, Canada. He subsequently returned to the UK in 2005 to Plymouth Marine Laboratory at a senior scientist until his move to Argonne National Laboratory and the University of Chicago in 2010. Currently, Professor Gilbert is the Director of the Microbiome Center and a Professor of Surgery at the University of Chicago. He is also Group Leader for Microbial Ecology at Argonne National Laboratory, Research Associate at the Field Museum of Natural History, Scientific Fellow at the Marine Biological Laboratory, and the Yeoh Ghim Seng Visiting Professorship in Surgery at the National University of Singapore. Dr. Gilbert uses molecular analysis to test fundamental hypotheses in microbial ecology. He has authored more than 250 peer reviewed publications and book chapters on metagenomics and approaches to ecosystem ecology. He is the founding Editor in Chief of mSystems journal. In 2014 he was recognized on Crain’s Business Chicago’s 40 Under 40 List, and in 2015 he was listed as one of the 50 most influential scientists by Business Insider, and in the Brilliant Ten by Popular Scientist. In 2016 he won the Altemeier Prize from the Surgical Infection Society, and the WH Pierce Prize from the Society for Applied Microbiology for research excellence.

Michael Martin, Ph.D., Head, Takeda Ventures, Inc.



Dr. Michael Martin is the head of Takeda Ventures, Inc. (TVI) and he is based in San Diego, CA. His professional background includes venture capital, pharma business development and broad R&D experiences with an integral role in the discovery and preclinical/clinical development of 17 innovative investigational drugs and 2 commercial products. Prior to TVI, Dr. Martin was most recently a member of Global Licensing and Business Development at Takeda, heading efforts for globally sourcing and transacting technologies and early stage pipeline programs. Dr. Martin joined Takeda in January 2012 through the acquisition of Intellikine where he was Vice President of Development. Additionally, he has held executive and senior management and scientific positions with TargeGen (acquired by Sanofi-Aventis), Arena Pharmaceuticals, and Monsanto Corporation. Dr. Martin earned his doctorate in Medicinal Chemistry from the University of Illinois and holds a M.S. degree in analytical chemistry and B.S. degrees in Chemistry and Mathematics.

Ed Mathers, Partner, NEA



Ed Mathers joined NEA as a Partner in August 2008 and is focused on biotechnology and specialty pharmaceuticals investments. He is a director of Liquidia Technologies, Ra Pharmaceuticals, Rhythm Pharmaceuticals, Envisia Therapeutics, Synlogic, Mirna Therapeutics, Lumos Pharma and Ziarco. He is also a member of NC State’s College of Sciences Foundation board. Previously he was a board member of Lumena (sold to Shire), Plexxikon (sold to Daiichi Sankyo), Intarcia, Satori Pharmaceuticals, Southeast Bio, MedImmune, LLC, and the Biotechnology Industry Organization (BIO).

10:00 AM–10:30 AM


10:30 AM–11:15 AM

Breakout: Unlocking Value in Digital Health

The smart digital health startup knows that having cool technology is not enough in moving the needle in healthcare in terms of outcomes and costs. Demonstrating value is key. Who are the successful ones in this arena? Which technologies have failed?

sponsored by BioEnterprise

Moderator: Steven Collens, CEO, MATTER



Steven Collens is CEO of MATTER, Chicago’s healthcare technology incubator. He also serves as senior advisor to Pritzker Group Venture Capital. Prior to assuming his current role, Collens was SVP at Pritzker Group, the investment firm led by Tony and J.B. Pritzker. In that capacity, he led the team that created 1871, Chicago’s center for digital startups. He previously worked at Abbott in a variety of domestic and international functions, including product management, policy and public affairs. Collens holds an MBA from Northwestern University’s Kellogg School of Management and a BA from Washington University in St. Louis.

Deborah Kilpatrick, Ph.D., Chief Executive Officer, Evidation Health



Deborah is the Chief Executive Officer of Evidation Health. Prior to this role, she served as the Chief Commercial Officer of genomic diagnostics company CardioDx. Earlier in her career, Deborah held multiple leadership roles at Guidant Corporation, including Research Fellow, Director of R&D, and Director of New Ventures in the Vascular Intervention Division. She serves on the Georgia Tech Advisory Board and is a Fellow of the American Institute of Medical and Biological Engineering. Deborah is a co-founder of the MedtechVision Conference, now held annually in Silicon Valley. She holds BS, MS and PhD degrees in mechanical engineering with a bioengineering focus from Georgia Tech.

Aram Nerpouni, President & CEO, BioEnterprise



As the president and chief executive officer of BioEnterprise, Aram Nerpouni leads industry changing initiatives, working with public and private entities, to grow the bioscience industry in Cleveland and Northeast Ohio. Prior to his current role, Aram functioned as BioEnterprise’s vice president of strategic development. In August 2012 he took over the leadership position. Aram Nerpouni brings strong international perspective to BioEnterprise, having spent more than 10 years helping U.S. companies develop sales, marketing and distribution strategies in emerging European, Asian and Latin American markets.

Aram received his MBA from Case Weatherhead School of Management in Cleveland and a BS in biology from Stanford University. He serves on the Boards of the Great Lakes Science Center, Cleveland School of Science and Medicine, and Child Guidance and Family Solutions.

Marti Nyman, Vice President, Business Development and Commercialization, Innovation Center of Excellence, UnitedHealth Care



Marti Nyman is the Vice President, Business Development and Commercialization for UnitedHealthcare. In his role, he is responsible for the assessment, structuring and commercial expansion of the company’s breakthrough innovations. Prior to this, Marti was Chief Client Development Officer for Ulteig Engineers, Inc., where he led the development and growth of new and existing clients across the company’s served market segments. Throughout his career, Marti has held business leadership and market growth roles at GE, UnitedHealth Group, Best Buy, Ericsson and ADC. With a passion for growth and innovation, he has led growth initiatives involving market strategy development, venture capital, new venture creation (M&A, Joint Ventures, Strategic Alliances), international market expansion, sales, marketing and operations management. Marti is also an adjunct instructor at the University of Minnesota’s Carlson School of Management, specializing in graduate studies in entrepreneurship and business formation.

Mark Tomaino, Operating Partner, Welsh, Carson, Anderson & Stowe @mark_tomaino


Mark Tomaino is an Operating Partner at Welsh, Carson, Anderson & Stowe, a New York City based private equity firm that invests, principally, in two markets, healthcare and information/business services. Mark’s focus is exclusively on healthcare technology investment opportunities, including deal generation, due diligence, execution and portfolio company monitoring. Mark has served on the board of directors of Matrix Medical Network and GetWellNetwork. Prior to September 2010, Mark served as Senior Vice President, Corporate Development and M&A at The TriZetto Group, a leading healthcare information technology company to the healthcare payer industry, where he had responsibility for developing and executing its external growth strategies, including mergers and acquisitions, strategic alliances, joint ventures, investments and capital raising activities. Mark initiated the $1.4 billion go-private transaction with Apax Partners in August 2008 ending TriZetto’s tenure as a NASDAQ-listed public company. Prior to joining TriZetto, Mark worked at Bausch & Lomb Incorporated in a variety of legal, strategy and business development capacities.

10:30 AM–11:15 AM

Breakout: Beyond the Pill and Product, Whither Now?

With the question of value looming, more and more companies are starting to focus on the importance of not only the drug or the device but the services that must be wrapped around the product to demonstrate both clinical value for patients and economic value for health systems. How has that changed perspectives of potential acquirers, VCs, as well as hospitals looking to do pilots?

Moderator: Joseph Johnson, Managing Director, L.E.K.



Joe Johnson is a Managing Director and Partner, as well as the head of L.E.K. Consulting’s New York office. He is one of the leaders in L.E.K.’s Healthcare Services practice and plays an instrumental role in helping senior executives across the industry develop and implement new strategies to address sweeping federal healthcare reforms that are having a significant impact in this market. He has more than 15 years of consulting experience managing and directing client engagements and has worked on a substantial number of strategic growth, operations and commercial due diligence projects across the healthcare services industry. His expertise in the Healthcare Services practice includes areas such as quality, healthcare IT, Medicare, Medicaid and provision of healthcare services, among others.

Dirk Schapeler, Head of LifeScience iHUB, Bayer



Dirk Schapeler is the Head of Bayer’s LifeScience iHUB innovation center that he founded in Silicon Valley. An engineer in electronics and mechanics he studied in Karlsruhe Germany. Dirk previously served as the CEO of Bayer’s ViviTouch subsidiary Artificial Muscle Inc. in Sunnyvale that he sold in 2013. He is a co-inventor of electro active polymers and owns more than 13 patents. He has been working in Automotive, Material Science and Healthcare for almost 2 decades in the US, Germany, France and Mexico. In his current role he focuses on the digitalization of the pharma, consumer care and crop science industry.


11:15 AM–11:30 AM


11:30 AM–12:15 PM

Fireside Chat: No Snake-oil Salesmen Allowed: Developing New Products with Physician Input

Moderator: Arundhati Parmar, VP and Editorial Director, MedCity News @Aparmarbb


Arundhati Parmar is VP and Editorial Director at MedCity News. Previously she was senior editor at UBM’s Medical Device + Diagnostic Industry and has been a business journalist for more than a decade. Arundhati has three degrees from three continents – a Bachelor of Arts in English from Jadavpur University, Kolkata, India; a Masters in English Literature from the University of Sydney, Australia and a Masters in Journalism from Northwestern University in Chicago. She has sworn never to enter a classroom again.VP and Editorial Director

Jack Stockert, Managing Director, Health2047 @Health2047


Jack is focused on driving innovations that improve the way people live and physicians practice. He is managing director at Health2047, an integrated innovation company with a mission to improve healthcare by bridging the gap between the medical and tech communities and leveraging the strengths of its founding partner, the AMA. As a physician who possesses strong analytic skills refined at McKinsey and a broad understanding of system-level issues gained at the WHO, Jack offers unique insights into the transformation needed in the healthcare industry.

Michael Tutty, Group Vice President - Professional Satisfaction and Practice Sustainability, American Medical Association



Michael Tutty, PhD, MHA is the Group Vice President of Professional Satisfaction and Practice Sustainability at the American Medical Association (AMA). Michael manages AMA’s efforts to identify, support, and grow the models of care delivery and payment that promote the long-term sustainability of and satisfaction with medical practice. Prior to joining the AMA, Michael had a number of roles at the University of Massachusetts Medical School (UMMS), most recently serving as the Director of the Office of Health Policy and Technology. Previously, Michael worked at the Boston Consulting Group (BCG) in their health care practice. Michael maintains an assistant professor faculty appointment in the Department of Family Medicine and Community Health at UMMS. Michael earned his BA in Government from Western New England College, his MHA from Clark University, and his PhD in Public Policy from the University of Massachusetts Boston.

12:15 PM–1:30 PM

Lunch + Research Presentation

1:30 PM–2:30 PM

Breakout: EXIT Stage Left – Trends In The Public Markets and M&As

Hear from an investment banker and finance experts about the trends that are driving IPOs, and the mergers and acquisitions space in the healthcare industry.

sponsored by Silicon Valley Bank

1:30 PM–2:30 PM

Breakout: The Collaborative Model for New Company Formation in Healthcare

Traditional life science companies are teaming up with tech companies and other entities to create unlikely marriages. What were the decisions internally that drove companies to create these combinations? Will products born from these collaborations change the landscape of therapies?

sponsored by McDermott Will & Emery

Sarah Hogan, Partner, McDermott Will & Emery



Sarah Hogan represents companies in the life sciences and digital health industries on structuring and negotiating intellectual property licenses, strategic collaborations and other complex commercial transactions – helping her clients leverage intellectual property assets and collaborate to develop and deliver innovative solutions that improve health and health care. Sarah uses her science background and comprehensive life sciences industry knowledge as an asset to understand critical business concerns and effectively manage complex issues. As a result of the diverse range of clients and transactions she manages, Sarah has in-depth understanding of the implications of each deal on various aspects of the business, including downstream transactions. Sarah is known for her practical approach – focusing on achieving business objectives while balancing legal risks and preserving her clients’ relationship with their partners.

Jared Josleyn, Partnership and Business Development Lead, Verily Life Sciences



Jared Josleyn is the Partnership and Business Development Lead at Verily Life Sciences. Jared oversees Verily’s partnership efforts and leads its strategic business development efforts. Prior to joining Verily in 2015, Jared was the Global Business Development Manager for Eli Lilly and Company’s animal health division, Elanco Animal Health and the Director of Business Development for E&A Industries, a private holding company based in Indianapolis, IN. Jared earned a Bachelor of Science in Economics from Purdue University, a MBA from the Indiana University Kelley School of Business, and a law degree from Indiana University School of Law.

2:30 PM–2:45 PM


2:45 PM–3:30 PM

Panel: The Evolving Payer-Provider Collaboration

With a new administration, certain tenets of the Affordable Care Act will be rolled back, but accountable care is not a genie that can be put back in the bottle. How are integrated health systems and standalone health systems working together with health plans and how are payer-providers attempting to rein in costs and provide quality care? How does this affect healthcare VCs?

Moderator: Bruce Japsen, Healthcare Columnist, Forbes @brucejapsen


Bruce Japsen writes about healthcare for Forbes and is the author of “Inside Obamacare: the Fix for America’s Ailing Health Care System.” He is a regular analyst on Fox News Channel’s “Forbes on Fox,” Chicago’s WBBM Newsradio and WTTW’s ChicagoTonight public affairs program. His work also has appeared in the New York Times, The Motley Fool and Chicago Medicine. He teaches for the University of Iowa School of Journalism’s as an instructor in the Master’s In Strategic Communication program

Gunjan Khanna, Partner, McKinsey



Gunjan Khanna is a Partner in McKinsey’s Pittsburgh Office and is a core member of the Healthcare Systems and Services (HSS) Practice. Since joining the firm in 2007, Gunjan has been involved in helping both Payors and Providers on a variety of strategic, operational, and technology topics. Gunjan also leads Healthcare practice’s knowledge research effort on Medicare, Population Health Management, and payor-provider collaborations. Before joining McKinsey, Gunjan worked with IBM T.J. Watson Research in their distributed systems group. Gunjan completed his doctorate and Masters from Purdue University in Electrical and Computer Engineering. He holds an undergraduate degree from Indian Institute of Technology (IIT), Delhi in Electrical Engineering.

Rachel Winokur, Chief Business Officer, Bright Health



Rachel Winokur is currently the Chief Business Officer of Bright Health, an insurance company offering exclusive network health plans in partnership with leading health systems.  Previously she was a senior executive at Aetna, where she helped found and lead Healthagen, Aetna's payer-neutral population health management business.  Rachel joined Aetna from the Carlyle Group, where she invested in healthcare companies for Carlyle's US Growth Equity Fund.  Prior to that role, she was a corporate officer of Datascope, a publicly-traded medical devices company, and spent several years in operations and business development with Bertelsmann, a global media company.  Rachel started her career at Goldman Sachs.  Rachel currently sits on the boards of HealthVerity and HealthReveal. She is also an Advisor to Greycroft Partners and AiCure. Rachel received an MBA from Stanford University's Graduate School of Business and a BSE with honors in  Biomedical Engineering and Electrical Engineering from Duke University.

3:30 PM–3:45 PM


3:45 PM–5:30 PM

Pitch Perfect Contest

A group of 40-50 startups representing all life sciences categories, who have had at least a seed funding round will pitch 3 judges — a mix of VCs and hospital innovation chiefs — LIVE about their product/company. Three-minute presentations are followed by 5-minute Q&A with judges on stage. Judges will have a score sheet to allocate points based on specified criteria: business idea, market opportunity, revenue model, founder’s experience and quality of presentation.

sponsored by OSF Healthcare

5:30 PM–7:00 PM

Networking Reception

Day 2: Thursday, May 18

8:00 AM–8:30 AM


8:30 AM–9:15 AM

Day 2 Opening Keynote

Christopher Ross, Chief Information Officer, Mayo Clinic



Cris Ross has 30 years prior experience in healthcare, technology, and government.  Prior to joining Mayo Clinic he held technology and business leadership roles with Surescripts, MinuteClinic, and UnitedHealth Group.  Previously he held various roles as a tech entrepreneur, financial manager, and Congressional aide.

He is chairman of the Board of the eHealth Initiative, and serves on the Boards of Directors of the Health Information Management Systems Society (HIMSS) and Zipnosis, an emerging telehealth vendor.  He was a member of the Health IT Standards Committee for the U.S. Department of Human Services from 2009-2016.

He has a Bachelor of Science degree in economics from the University of Minnesota and MBA degree from the Yale School of Management.

9:15 AM–10:15 AM

Panel: Removing Barriers to Precision Medicine

Very few new drugs are being approved with companion diagnostics although new drug approvals from FDA have a higher chance of being approved if tied to a biomarker. What are the barriers to developing and commercializing precision medicine and what strategies are being deployed to advance precision medicine? What is the role of hospitals in this space?

Moderator: Nitin Naik, Global Vice President, Life Sciences, Frost & Sullivan



Nitin Naik is Global Vice President, Life Sciences at Frost & Sullivan. Nitin has close to 20 years of healthcare industry experience, including 12 plus years of consulting expertise within pharmaceuticals, diagnostics and biotechnology sectors. He is adept at leading cross-functional teams and building top management support for strategic initiatives. He has executed multiple assignments in strategy consulting, business development and licensing, portfolio management and e-marketing with GE Healthcare (national distributor), Frost & Sullivan Asia, and A*STAR Singapore.

Manoja Lecamwasam, Ph.D., Executive Director, Dignity Health



Manoja Lecamwasam is the Executive Director of the Dignity Health Intellectual Property Office. In her role, she provides leadership and guidance for the development of IP-related strategic and operational initiatives for Dignity Health, manages the evaluation, protection and commercialization functions of the organization’s IP and manages a team of IP management professionals. Dr. Lecamwasam is also a member of the Strategic Innovation function and was Dignity Health’s business lead for the establishment of the Precision Medicine Alliance (PMA), a joint venture with Catholic Health Initiatives (CHI) that will provide genomic-based decision support tools to Dignity Health’s community oncologists at point of care. She is currently a governance board member of the PMA. Prior to joining Dignity Health, Dr. Lecamwasam served as a senior licensing associate/licensing associate in the Office of Corporate Sponsored Research and Licensing at Massachusetts General Hospital. Dr. Lecamwasam holds a PhD degree in molecular microbiology from Tufts University School of Medicine, a MBA from the University of Phoenix, Phoenix, AZ, a MSc degree in molecular biology from Northeastern University, MA and a BA with honors in biology from Mills College in Oakland, CA.

Franziska Moeckel, Assistant Vice President, Personalized Health, Inova Center for Personalized Health



Franziska Moeckel is the Assistant Vice President, Personalized Health at Inova. In her role, Franziska is leading business operations and product launch activities for genomic testing as part of an in-house, CLIA-certified genomics laboratory, and is assessing and promoting new ‘omics features for clinical practice, including consumer-directed and direct-to- consumer products and services. As part of the new Inova Center for Personalized Health team, she is providing strategic direction and thought leadership around the integration of precision medicine and individualized wellness.

Richard J. Wenstrup, Chief Medical Officer, Myriad Genetics



Richard J. Wenstrup, chief medical officer, joined Myriad Genetics in 2006 as chief medical officer for Myriad Genetic Laboratories where he led the Clinical Affairs and Corporate Medical Services Departments.  Prior to joining Myriad, he was internationally recognized for his academic research in heritable disorders of connective tissue and the skeleton and served as a tenured professor of Pediatrics (Human Genetics) at Cincinnati Children’s Hospital and professor of Biomedical Engineering at the University of Cincinnati.  Dr. Wenstrup has published more than 100 peer-reviewed papers on human and mouse genetics.  He served as past president of the medical advisory board of the Ehlers-Danlos National Foundation and at the Osteogenesis Imperfecta Foundation (OIF) and as chair of the scientific advisory board of the OIF.   He currently is a member of the scientific advisory board of the Marfan Foundation. Dr. Wenstrup received his medical degree from the University of Cincinnati College of Medicine and completed a pediatrics residency at the University of Minnesota Hospital and a fellowship in medical genetics at the University of Washington.

10:15 AM–10:45 AM


10:45 AM–11:45 AM

Breakout: How Are Concerns About Cost and Pricing Affecting Innovation and Investment?

When EpiPen gets mocked at the Emmys, you know the issue of drug pricing is only likely to get heated. There’s also a lot of attention being paid to expensive technologies and its impact on the cost of healthcare. Listen to a 10-minute presentation about healthcare innovation and economics, followed by a discussion on how the issue may change what therapies are developed and reimbursed, and how drug pricing worries may be affecting investment.

Moderator: Ed Silverman, Pharmalot Columnist, Senior Writer, STAT @pharmalot


Ed Silverman, senior writer and Pharmalot columnist, has covered the pharmaceutical industry for the past two decades. He previously worked at The Wall Street Journal, The Star-Ledger of New Jersey, New York Newsday and Investor’s Business Daily, among other publications. Along with several former Wall Street Journal colleagues, Ed was a Pulitzer Prize finalist in explanatory journalism for a series of stories on prescription pricing. He earned an accounting degree from Binghamton University and a master’s in journalism from New York University. Ed enjoys reading, spending time with his family, and walking the official Pharmalot mascots.

David Berry, M.D., Ph.D., General Partner, Flagship Pioneering



David Berry, M.D., Ph.D., joined Flagship Pioneering in 2005. At Flagship, David has co-founded and helped build more than 20 companies across life sciences, technology and sustainability, including Seres Therapeutics (NASDAQ: MCRB), Joule Unlimited, Evelo Biosciences, Eleven Biotherapeutics (NASDAQ: EBIO), LS9 (acquired by Renewable Energy Group), Axcella Health and Indigo Agriculture. David holds over 200 patents and patent applications.  The thread uniting David’s work is an abiding enthusiasm for solving complex global challenges. He is particularly interested in the issue of sustainability because of its unprecedented intricacy—which applies broadly to our healthcare system, our environment and beyond. David is the recipient of many awards and honors for his work, including 2014 Young Global Leader by the World Economic Forum, 2013 PharmaVOICE 100 as one of the 100 most inspiring people in the life-sciences industry; inclusion on the 2012 Boston Business Journal’s 40 under 40 list, and one of 12 Innovators Reshaping Reality by the U.S. State Department in 2008.

William McKeon, EVP and Chief Strategy and Operating Officer, Texas Medical Center



William McKeon is the Executive Vice President, Chief Strategy & Operating Officer of the Texas Medical Center. He is responsible for driving strategic, operational and programmatic initiatives across the Texas Medical Center’s member institutions to enhance its leadership position in the life sciences. Mr. McKeon has served as an executive for some of the leading companies and institutions in the world, including; Du Pont, Stanford University Medical Center, US Oncology, Medtronic, MicroPort (Shanghai) and Cellnovo. Mr. McKeon was twice awarded the ComputerWorld- Smithsonian Award in Medicine.

Sebastian Schneeweiss, Professor of Medicine and Epidemiology, Harvard Medical School



Sebastian Schneeweiss, MD, ScD is a physician and pharmacoepidemiologist with 20 years of experience in analyzing healthcare databases. As a Professor of Medicine and Epidemiology at Harvard Medical School he is a leading researcher in risk-adjustment and rapid cycle analytics of large longitudinal healthcare databases. Sebastian is Past President of the International Society for Pharmacoepidemiology and is Fellow of the American College of Epidemiology and the American College of Clinical Pharmacology. He is advisor to FDA, EMA, CMS, PCORI and NIH. Sebastian received his medical training at the University of Munich and his doctorate degree in Pharmacoepidemiology from Harvard.

10:45 AM–11:45 AM

Breakout: What Determines Which Digital Health Technologies Hospitals Will Embrace?

Hear from hospital execs on the technologies that can reduce or eliminate pain points within hospitals, whether it be to better care for at-risk patient populations or boosting hospital efficiency. When approaching hospitals for pilots, what are best practices and how to identify which hospitals are mere window shoppers instead of a true customer?

Moderator: Karen Griffith Gryga, Chief Investment Officer, DreamIt @karengg


Karen Griffith Gryga is an experienced venture capitalist, investor and entrepreneur with over 20 years of startup and emerging growth company experience. Karen is Chief Investment Officer for DreamIt. Karen is also co-founder of Dreamit Health and founder of the DreamIt Athena program which focuses on female founders. DreamIt is a leading technology accelerator for entrepreneurs which has worked with and launched close to 300 companies since 2008 including SeatGeek, HouseParty, LevelUp, Biomeme, Biobots, Parsely, MindSnacks and Adaptly. Dreamit is the only growth accelerator designed for mature startups. Post-seed companies with product market fit, some revenue, or early traction are left with limited funding options and resources to scale before qualifying for today's "super-sized" A rounds. We put our companies in front of customers, key strategic partners to drive pilot programs and distribution before we match them with larger venture funds and investor groups to raise follow-on funding. The DreamIt Fund focuses primarily on the follow on investments of DreamIt companies exhibiting strong growth and traction. Dreamit Fund has been named as one of the Top 30 venture capital firms in the United States. We are also one of the most active early stage healthcare investors in the country.

Lyle Berkowitz, M.D., Director of Innovation, Northwestern Medicine @DrLyleMD


Lyle Berkowitz, MD, FACP, FHIMSS is the Director of Innovation for Northwestern Medicine, Executive Director of the Szollosi Healthcare Innovation Program, and a practicing primary care physician. He is also co-founder and Chairman of healthfinch, and serves on the Board of Directors for Oneview Healthcare, the Governance Board of the Innovation Learning Network, the Advisory Board of the Association of Medical Directors of Information Systems, the Editorial Boards for Clinical Innovation + Technology and Healthcare Innovation News, and is the author of Innovation with Information Technologies in Healthcare.

Todd Dunn, Director of Innovation in Information Systems, Intermountain Healthcare



Todd Dunn is the Director of Innovation in Information Systems for Intermountain Healthcare. He currently leads Intermountain’s Healthcare Transformation Lab. His passion is influencing the strategy, mindset, and toolset that enables effective innovation. His purpose is innovating to help people. Todd often spends his personal time advising startups and working with early stage companies. He was invited by Alex Osterwalder to be an exclusive pre-reader and contributor to Alex’s most recent book, Value Proposition Design. Todd is the author of “The Seven Deadline Healthcare Startups Sins” on Steve Blank’s website. Todd’s innovative program called “Design for People” is highlighted in Clayton Christensen’s book, Competing Against Luck. Todd received his undergraduate degree in Marketing from the University of Utah and his MBA from Michigan State University.

Scott Honken, VP of Health Plan Success, Omada Health



Scott Honken currently serves as the Vice President for Health Plan Success at Omada Health. He is accountable for expanding business opportunities with all of Omada’s health plan partners and leading the account teams that maintain these relationships. He previously led the health plan sales team at Omada, focused on expanding health plan and payer coverage of Omada’s program. Omada Health is the largest CDC-recognized provider of the National Diabetes Prevention Program, integrating design, data science, and personalization in the company’s digital platform. Prior to his time at Omada, Scott held several positions at Catamaran, including launching the company’s Innovation Center, and leading the clinical consulting team. Prior to his time at Catamaran, Scott coordinated managed care pharmacy programs for Mayo Clinic Health Solutions. Scott holds and MBA and PharmD from Creighton University, and a BA in Chemistry from Central College.

Tom Sudow, Director Business Development, Cleveland Clinic Innovations



Tom Sudow is Director of Business Development for the Global Cardiovascular Innovation Center (GCIC), a product development consortium, where he is part of a team managing a portfolio of over 40 companies.  He works with the Global Healthcare Innovation Alliance and as an Advisor to eHealth Venture. Tom has spoken internationally and also at the White House on digital health.  As a community leader he was chair of the Northern Ohio Area Chambers of Commerce (NOACC) and several other organizations. He is also a frequent guest columnist and speaker and  has been recognized with awards from many economic development and community organizations.

11:45 AM–12:00 PM

Pitch Perfect Contest Winners Announcement

12:00 PM–12:30 PM

Day 2 Closing Keynote

12:30 PM

Closing Remarks + Conference Adjourn



MedCity INVEST is presented by MedCity News, producer of unique innovation-focused events across the healthcare ecosystem, and MHIN (Mid-America Healthcare Investors Network), a non-profit organization composed of more than 40 venture capital firms.



Who Attends MedCity INVEST